Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Capsugel and Cardax to Collaborate on Astaxanthin Products Development

Published: Thursday, August 21, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
Collaboration leverages Capsugel’s proprietary lipid-based technologies for potential development of consumer health products.

Capsugel and Cardax, Inc. have announced a collaboration to develop unique astaxanthin products for the consumer health market. The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin products on the market. Astaxanthin is currently used as a specialized antioxidant.

The astaxanthin products will be jointly developed using Capsugel’s proprietary lipid multi-particulate (LMP) technology, which encapsulates dissolved or suspended active ingredients into spherical lipid matrix particles for oral dosage in capsules, sachets, suspensions or tablets.

LMP technology utilizes a range of approved lipids to deliver the benefits of lipid-based formulations in multi-particulate format, including improved bioavailability, controlled release and effective taste-masking. The companies will seek a strategic partner for retail commercialization in the mass market. Specific business terms were not disclosed.

“Our strategic partnership with Cardax provides an opportunity to be at the forefront of developing unique astaxanthin products for consumer health applications,” said Amit Patel, Capsugel SVP and Dosage Form Solutions President. “Our premier bioavailability enhancement technology suite and lipid-based formulation expertise, coupled with our encapsulation know how and infrastructure, will be leveraged to meet our partner’s product profile and commercial goals of a high quality final dosage form.”

“Our collaboration with Capsugel provides the formulation expertise and infrastructure necessary for the advancement of proprietary astaxanthin products for consumer health applications,” added David G. Watumull, Cardax President and CEO.

Watumull continued, “Participation in more of the consumer health value chain as a true partner with Capsugel could add substantially to our revenues, and the new intellectual property anticipated from this collaboration may provide a meaningful competitive advantage.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Capsugel Completes Acquisitions of Xcelience and Powdersize
Acquisitions provide Capsugel with specialized clinical trial manufacturing and supply capabilities.
Thursday, January 07, 2016
Capsugel to Acquire Xcelience and Powdersize
Xcelience provides the company with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms.
Thursday, December 17, 2015
Capsugel Expanding Pharmaceutical Product Development and Manufacturing Capabilities
Investment accommodates the company’s growing pipeline of pharmaceutical customer projects and brings a broader range of technologies closer to its European customers.
Thursday, August 06, 2015
Capsugel Unveils New Spray-Dried Dispersion Commercial Manufacturing Facility
Significantly expands the commercial manufacturing capability at its Bend, Ore. Site.
Thursday, July 02, 2015
Capsugel Extends Inhaled Biotherapeutics Delivery Capability to Phase 2 Clinical Trials
Company partnering with customers to expand the use of inhalation technologies to treat a wider range of diseases.
Thursday, May 07, 2015
Capsugel Awarded EXCiPACT™ Certifications
First hard capsule manufacturer to receive this important third-party recognition.
Wednesday, October 08, 2014
Capsugel Expands Global Manufacturing for Finished Dosage Forms
DFS unit expands capabilities for hormonal, high-potency compounds.
Thursday, September 26, 2013
Capsugel to Acquire Bend Research
Enhances bioavailability expertise.
Thursday, September 12, 2013
Capsugel Unveils Quality Control Laboratory
South Carolina based facility provides global center of excellence for the company.
Monday, December 10, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!